slipped 1/4 to 97 in after-hours trading following news that a committee of the
recommended suspending marketing approval for the company's lately maligned antibiotic
. On Wednesday, the drug maker said the
Food and Drug Administration
urged physicians to limit prescriptions for Trovan after 14 cases of acute liver failure were strongly associated with the drug. As analysts downgraded the stock and estimates for Trovan sales were slashed, PFE recorded a 14.8% loss for the week.
In other postclose news (earnings estimates from
; earnings reported on a diluted basis unless otherwise specified):
Earnings/revenue reports and previews
reported a fourth-quarter loss of $3.76 a share, including charges. The five-analyst outlook called for an operating loss of 61 cents vs. the year-ago loss of 25 cents.
Offerings and stock actions
said a group of
-affiliated entities plans to sell up to 4.8 million of its remaining shares of the company's stock in an underwritten secondary offering. Borg-Warner also said it plans to close its purchase of 4.4 million of its shares from the Merrill group June 14.
Central Garden & Pet
boosted its current buyback program to $105 million from $80 million.
priced a planned 4.5 million-share secondary offering at 19 a share.
filed for a 2.25 million-share offering.
Southern Connecticut Gas
unit filed for an increase of 10.56%, or $24.2 million, in its base rates.